David Lawson MD
Academic Appointment
- Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University
- Professor of Medicine, Department of Medicine, Emory University School of Medicine
Education
Degrees
- MD from Emory University School of Medicine
- Bachelors of Arts from Duke University
Research
Focus
- My primary effort is in clinical trials for malignant melanoma. We continue to have a variety of pharmaceutical trials available at any one time. I am PI on national study E4697, which is in final evaluation stage. As Chair of the Melanoma and Pigmented Lesion Center, I will try over the next five years to help build the basic science effort in melanoma and increase our effort in translational studies, especially studies based on work done at Emory.
Publications
-
Practical resiliency training for healthcare workers during COVID-19: results from a randomised controlled trial testing the Community Resiliency Model for well-being support.
BMJ Open Qual Volume: 11
11/01/2022 Authors: Duva IM; Higgins MK; Baird M; Lawson D; Murphy JR; Grabbe L -
Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition.
Front Oncol Volume: 12 Page(s): 836845
01/01/2022 Authors: Knochelmann HM; Ware MB; Rali A; Linderman S; Shantha JG; Lawson DH; Yushak M; Swerlick R; Paulos CM; Yeh S -
Correlates of financial toxicity in adult cancer patients and their informal caregivers.
Support Care Cancer Volume: 30 Page(s): 217 - 225
01/01/2022 Authors: Sadigh G; Switchenko J; Weaver KE; Elchoufi D; Meisel J; Bilen MA; Lawson D; Cella D; El-Rayes B; Carlos R -
Melanoma Cell Intrinsic GABAA Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity.
Int J Radiat Oncol Biol Phys Volume: 109 Page(s): 1040 - 1053
03/15/2021 Authors: Pomeranz Krummel DA; Nasti TH; Kaluzova M; Kallay L; Bhattacharya D; Melms JC; Izar B; Xu M; Burnham A; Ahmed T -
Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy.
J Immunother Cancer Volume: 8
10/01/2020 Authors: Buchwald ZS; Nasti TH; Lee J; Eberhardt CS; Wieland A; Im SJ; Lawson D; Curran W; Ahmed R; Khan MK -
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Br J Cancer Volume: 123 Page(s): 1228 - 1234
10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA -
Exosome-Containing Preparations From Postirradiated Mouse Melanoma Cells Delay Melanoma Growth InVivo by a Natural Killer Cell-Dependent Mechanism.
Int J Radiat Oncol Biol Phys Volume: 108 Page(s): 104 - 114
09/01/2020 Authors: Jella KK; Nasti TH; Li Z; Lawson DH; Switchenko JM; Ahmed R; Dynan WS; Khan MK -
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist Volume: 25 Page(s): e528 - e535
03/01/2020 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H -
Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases.
Sci Adv Volume: 6 Page(s): eaav7504
02/01/2020 Authors: Tan S; Yang H; Xue S; Qiao J; Salarian M; Hekmatyar K; Meng Y; Mukkavilli R; Pu F; Odubade OY -
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist
12/05/2019 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H -
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Invest New Drugs Volume: 37 Page(s): 1198 - 1206
12/01/2019 Authors: Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL -
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
BMC Cancer Volume: 19 Page(s): 857
08/29/2019 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL -
T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
Cancer Immunol Immunother Volume: 67 Page(s): 1767 - 1776
11/01/2018 Authors: Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ -
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
J Immunother Cancer Volume: 6 Page(s): 76
07/27/2018 Authors: Clark JI; Singh J; Ernstoff MS; Lao CD; Flaherty LE; Logan TF; Curti B; Agarwala SS; Taback B; Cranmer L -
Insights into the Psychology of Trauma Should Inform the Practice of Oncology.
Oncologist Volume: 23 Page(s): 750 - 751
07/01/2018 Authors: Lawson KC; Lawson DH -
Radiologic and Histopathologic Correlation of Different Growth Patterns of Metastatic Uveal Melanoma to the Liver.
Ophthalmology Volume: 125 Page(s): 597 - 605
04/01/2018 Authors: Liao A; Mittal P; Lawson DH; Yang JJ; Szalai E; Grossniklaus HE -
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Mol Cell Volume: 69 Page(s): 923 - 937.e8
03/15/2018 Authors: Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang H-B; Pan Y; Liu S -
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
BMC Cancer Volume: 18 Page(s): 130
02/05/2018 Authors: Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR -
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab.
J Immunother Cancer Volume: 6 Page(s): 11
01/30/2018 Authors: Cafuir L; Lawson D; Desai N; Kesner V; Voloschin A -
Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
Am J Clin Oncol Volume: 40 Page(s): 444 - 450
10/01/2017 Authors: Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK -
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
Clin Cancer Res Volume: 23 Page(s): 5034 - 5043
09/01/2017 Authors: Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM -
HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.
J Biol Chem Volume: 292 Page(s): 10142 - 10152
06/16/2017 Authors: Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang H-B; Arbiser JL; Pollack BP -
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
J Cancer Res Clin Oncol Volume: 143 Page(s): 439 - 445
03/01/2017 Authors: Atkinson TM; Hay JL; Shoushtari A; Li Y; Paucar DJ; Smith SC; Kudchadkar RR; Doyle A; Sosman JA; Quevedo JF -
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.
Melanoma Manag Volume: 4 Page(s): 13 - 37
03/01/2017 Authors: Johnson MM; Leachman SA; Aspinwall LG; Cranmer LD; Curiel-Lewandrowski C; Sondak VK; Stemwedel CE; Swetter SM; Vetto J; Bowles T -
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.
Cell Metab Volume: 25 Page(s): 358 - 373
02/07/2017 Authors: Xia S; Lin R; Jin L; Zhao L; Kang H-B; Pan Y; Liu S; Qian G; Qian Z; Konstantakou E -
Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Am J Clin Oncol Volume: 40 Page(s): 27 - 34
02/01/2017 Authors: Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS -
The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.
Melanoma Res Volume: 26 Page(s): 595 - 603
12/01/2016 Authors: Danish HH; Patel KR; Switchenko JM; Gillespie TW; Jhaveri J; Chowdhary M; Abugideiri M; Delman KA; Lawson DH; Khan MK -
Complete response to high-dose IL-2 and enhanced IFN+Th17: TREG ratio in a melanoma patient.
Melanoma Res Volume: 26 Page(s): 535 - 539
10/01/2016 Authors: Diller ML; Kudchadkar RR; Delman KA; Lawson DH; Ford ML -
BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
Melanoma Res Volume: 26 Page(s): 387 - 394
08/01/2016 Authors: Patel KR; Chowdhary M; Switchenko JM; Kudchadkar R; Lawson DH; Cassidy RJ; Prabhu RS; Khan MK -
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
J Mol Diagn Volume: 18 Page(s): 299 - 315
03/01/2016 Authors: Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS -
Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma.
Melanoma Res Volume: 26 Page(s): 35 - 41
02/01/2016 Authors: Oliver DE; Patel KR; Switchenko J; Parker D; Lawson DH; Delman KA; Kudchadkar RR; Khan MK -
BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy.
Onco Targets Ther Volume: 9 Page(s): 7149 - 7159
01/01/2016 Authors: Chowdhary M; Patel KR; Danish HH; Lawson DH; Khan MK -
Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients.
J Immunother Volume: 39 Page(s): 355 - 366
01/01/2016 Authors: Diller ML; Kudchadkar RR; Delman KA; Lawson DH; Ford ML -
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.
J Immunother Cancer Volume: 4 Page(s): 44
01/01/2016 Authors: Amin A; Lawson DH; Salama AKS; Koon HB; Guthrie T; Thomas SS; O'Day SJ; Shaheen MF; Zhang B; Francis S -
Balancing Inflammation: The Link between Th17 and Regulatory T Cells.
Mediators Inflamm Volume: 2016 Page(s): 6309219
01/01/2016 Authors: Diller ML; Kudchadkar RR; Delman KA; Lawson DH; Ford ML -
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
J Clin Oncol Volume: 33 Page(s): 4066 - 4076
12/01/2015 Authors: Lawson DH; Lee S; Zhao F; Tarhini AA; Margolin KA; Ernstoff MS; Atkins MB; Cohen GI; Whiteside TL; Butterfield LH -
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.
Neuro Oncol Volume: 17 Page(s): 1312 - 1321
10/01/2015 Authors: Patel KR; Lawson DH; Kudchadkar RR; Carthon BC; Oliver DE; Okwan-Duodu D; Ahmed R; Khan MK -
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Mol Cell Volume: 59 Page(s): 345 - 358
08/06/2015 Authors: Kang H-B; Fan J; Lin R; Elf S; Ji Q; Zhao L; Jin L; Seo JH; Shan C; Arbiser JL -
FUSOKINE-AUGMENTED B CELLS FOR CANCER IMMUNOTHERAPY
CYTOTHERAPY Volume: 17 Page(s): S25 - S25
06/01/2015 Authors: Deng J; Pennati A; Yuan S; Kudchadkar R; Lawson DD; Galipeau J -
A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma
Volume: 33
05/20/2015 Authors: Clark J; Ernstoff MS; Milhem MM; Lao CD; Lawson DH; Flaherty LE; Luna TL; Aung S -
A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).
Volume: 33
05/20/2015 Authors: Amin A; Lawson DH; Salama AK; Koon HB; Guthrie TH; Thomas SS; O'Day S; Shaheen MF; Zhang B; Francis S -
Analysis of CTLA4 expression on T regulatory cells in patients with advanced stage melanoma in the setting of high dose IL-2 (HDIL-2)
Volume: 33
05/20/2015 Authors: Diller ML; Eysmans CE; Lawson DH; Delman KA; Kudchadkar RR; Ford M -
Melanoma risk prediction of a validated genetic signature compared to the AJCC online predictor
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Volume: 72 Page(s): AB172 - AB172
05/01/2015 Authors: Ferris L; Cook R; Wilkinson J; Lassen N; Johnson C; Oelschlager K; Stone J; Maetzold D; Russell M; Delman K -
Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
J Am Acad Dermatol Volume: 72 Page(s): 780 - 5.e3
05/01/2015 Authors: Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE -
The emerging role of radiotherapy for desmoplastic melanoma and implications for future research.
Melanoma Res Volume: 25 Page(s): 95 - 102
04/01/2015 Authors: Oliver DE; Patel KR; Parker D; Delman KA; Lawson DH; Kudchadkar RR; Khan MK -
Gene Expression Profile (GEP) Enhances Prognostic Value of Sentinel Lymph Node Biopsy (SLNB) in a Cohort of Patients with Head and Neck Melanoma
Volume: 22 Page(s): S121 - S121
02/01/2015 Authors: Diller M; Wilkinson J; Jackson G; Greisinger A; Amaria R; Gonzalez R; Stone J; Ferris L; Gerami P; Wayne J -
Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma.
Am J Clin Oncol Volume: 38 Page(s): 119 - 125
02/01/2015 Authors: Okwan-Duodu D; Pollack BP; Lawson D; Khan MK -
Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
J Immunother Volume: 38 Page(s): 80 - 84
01/01/2015 Authors: Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S -
Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.
Clin Cancer Res Volume: 21 Page(s): 175 - 183
01/01/2015 Authors: Gerami P; Cook RW; Wilkinson J; Russell MC; Dhillon N; Amaria RN; Gonzalez R; Lyle S; Johnson CE; Oelschlager KM -
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Am J Clin Oncol Volume: 37 Page(s): 580 - 584
12/01/2014 Authors: Marcus DM; Lowe M; Khan MK; Lawson DH; Crocker IR; Shelton JW; Melton A; Maynard N; Delman KA; Carlson GW -
Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Volume: 23
11/01/2014 Authors: Owonikoko TK; Lewis C; Busari AK; Kim S; Chen Z; Lawson DH; Carthon BC; El-Rayes BF; Khuri FR; Kauh J -
Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response.
Cancer Res Volume: 74 Page(s): 4133 - 4144
08/01/2014 Authors: Deng J; Yuan S; Pennati A; Murphy J; Wu JH; Lawson D; Galipeau J -
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
JAMA Volume: 311 Page(s): 2397 - 2405
06/18/2014 Authors: Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH -
Gene expression profile test (GEP) prediction of metastasis-free (MFS) and overall survival (OS) in a cohort of cutaneous melanoma (CM) patients undergoing sentinel lymph node biopsy (SLNB).
Volume: 32
05/20/2014 Authors: Lawson DH; Russell MC; Wilkinson J; Jackson GL; Greisinger A; Amaria RN; Gonzalez R; Lyle S; Johnson C; Oelschlager KM -
Outcome with stereotactic radiosurgery (SRS) and ipilimumab (Ipi) for malignant melanoma brain metastases (mets).
Volume: 32
05/20/2014 Authors: Shoukat S; Marcus DM; Rizzo M; Lawson DH; Khosa F; Liu Y; Patel KR; Khan MK -
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Cancer J Volume: 20 Page(s): 18 - 24
01/01/2014 Authors: Flaherty L; Hamid O; Linette G; Schuchter L; Hallmeyer S; Gonzalez R; Cowey CL; Pavlick A; Kudrik F; Curti B -
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.
J Immunother Cancer Volume: 2 Page(s): 33
01/01/2014 Authors: Ravi S; Spencer K; Ruisi M; Ibrahim N; Luke JJ; Thompson JA; Shirai K; Lawson D; Bartell H; Kudchadkar R -
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Nat Rev Clin Oncol Volume: 10 Page(s): 588 - 598
10/01/2013 Authors: Kaufman HL; Kirkwood JM; Hodi FS; Agarwala S; Amatruda T; Bines SD; Clark JI; Curti B; Ernstoff MS; Gajewski T -
The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings.
Neuropsychopharmacology Volume: 38 Page(s): 1921 - 1928
09/01/2013 Authors: Musselman D; Royster EB; Wang M; Long Q; Trimble LM; Mann TK; Graciaa DS; McNutt MD; Auyeung NSF; Oliver L -
CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).
Volume: 31
05/20/2013 Authors: Hodi FS; Amen A; Saenger YM; Pennock GK; Guthrie TH; Salama AK; Flaherty LE; Koon HB; Lawson DH; Shaheen MF -
Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020
Volume: 31
05/20/2013 Authors: Kaufman H; Lutzky J; Clark J; Margolin KA; Lawson DH; Amin A; Collichio FA; Pecora A; Urba WJ; Bennett KL -
Outcome with stereotactic radiosurgery (SRS) and ipilimumab (Ipi) for malignant melanoma brain metastases
Volume: 31
05/20/2013 Authors: Shoukat S; Marcus DM; Rizzo M; Lawson DH; Liu Y; Khan MK -
Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM)
Volume: 31
05/20/2013 Authors: Carvajal RD; Sosman JA; Quevedo F; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski T; Lutzky J; Lawson DH -
Automated and manual human papilloma virus in situ hybridization and p16 immunohistochemistry: comparison in metastatic oropharyngeal carcinoma.
Acta Cytol Volume: 57 Page(s): 633 - 640
01/01/2013 Authors: Fatima N; Cohen C; Lawson D; Siddiqui MT -
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
J Transl Med Volume: 10 Page(s): 236
11/21/2012 Authors: Ribas A; Chesney JA; Gordon MS; Abernethy AP; Logan TF; Lawson DH; Chmielowksi B; Glaspy JA; Lewis K; Huang B -
Combined double CK5/P63 stain: useful adjunct test for diagnosing pulmonary squamous cell carcinoma.
Diagn Cytopathol Volume: 40 Page(s): 943 - 948
11/01/2012 Authors: Fatima N; Cohen C; Lawson D; Siddiqui MT -
Selective Internal Yttrium-90 Radioembolization Therapy (90Y SIRT) in patients with Unresectable Metastatic Melanoma (MM) to Liver, Refractory to Systemic therapy: Analysis of Safety, Survival and Factors Associated with prolonged Survival
Volume: 56 Page(s): 836A - 837A
10/01/2012 Authors: Prajapati HJ; Lawal TO; Lawson DH; Chen Z; Kim HS -
Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
J Vasc Interv Radiol Volume: 23 Page(s): 943 - 948
07/01/2012 Authors: Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS -
A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
Volume: 30
05/20/2012 Authors: Owonikoko TK; Harvey RD; Kauh JS; Lewis CM; Hossain MS; Akintayo AO; Merriewether AR; Chen Z; Hawk NN; Saba NF -
Clinical experience of a targeted TCR-IL2 fusion protein in combination with cisplatin (CDDP) in patients (pts) with metastatic melanoma
Volume: 30
05/20/2012 Authors: Milhem MM; Weber JS; Amin A; Agarwala SS; Lawson DH; Thompson JA; O'Day S; Pennock GK; Richards JM; Kuzel T -
A single-arm, open-label, US expanded access study of vemurafenib in patients with metastatic melanoma.
Volume: 30
05/20/2012 Authors: Schuchter LM; Flaherty LE; Hamid O; Linette GP; Hallmeyer S; Gonzalez R; Cowey CL; Pavlick AC; Kudrik FJ; Lawson DH -
Gene expression profile signature (DecisionDx-Melanoma) to predict visceral metastatic risk in patients with stage I and stage II cutaneous melanoma.
Volume: 30
05/20/2012 Authors: Dhillon N; Rogers AR; Delman KA; Maetzold D; Oelschlager KM; Lyle S; Jackson GL; Greisinger A; Parker D; Cook RW -
SOX10 Expression in Malignant Melanoma, Carcinomas, and Normal Tissues
Volume: 25 Page(s): 131A - 131A
02/01/2012 Authors: Rashed A; Gonzalez R; Lawson D; Wang J; Cohen C -
SOX10 Expression in Malignant Melanoma, Carcinomas, and Normal Tissues
Volume: 92 Page(s): 131A - 131A
02/01/2012 Authors: Rashed A; Gonzalez R; Lawson D; Wang J; Cohen C -
Image Cytometric HER2 in Gastric Carcinoma - Is a New Algorithm Needed?
Volume: 92 Page(s): 160A - 160A
02/01/2012 Authors: Feiger B; Ormenisan C; Lawson D; Wang J; Cohen C -
Emerin Immunohistochemistry: A Useful Ancillary Test for the Identification of Papillary Thyroid Carcinoma
Volume: 25 Page(s): 145A - 145A
02/01/2012 Authors: Hinrichs BH; Kinsella MD; Lawson D; Cohen C; Siddiqui MT -
Emerin Immunohistochemistry: A Useful Ancillary Test for the Identification of Papillary Thyroid Carcinoma
Volume: 92 Page(s): 145A - 145A
02/01/2012 Authors: Hinrichs BH; Kinsella MD; Lawson D; Cohen C; Siddiqui MT -
Immunohistochemical Analysis of Six1 in Hepatocellular Carcinoma: Correlation with Proliferation, Prognostic Parameters, and Outcome
Volume: 92 Page(s): 425A - 426A
02/01/2012 Authors: Wang J; Lawson D; Cohen C -
Immunohistochemical Analysis of Six1 in Hepatocellular Carcinoma: Correlation with Proliferation, Prognostic Parameters, and Outcome
Volume: 25 Page(s): 425A - 426A
02/01/2012 Authors: Wang J; Lawson D; Cohen C -
Image Cytometric HER2 in Gastric Carcinoma-Is a New Algorithm Needed?
Volume: 25 Page(s): 160A - 160A
02/01/2012 Authors: Feiger B; Ormenisan C; Lawson D; Wang J; Cohen C -
Rising incidence of mucosal melanoma of the head and neck in the United States.
J Skin Cancer Volume: 2012 Page(s): 231693
01/01/2012 Authors: Marcus DM; Marcus RP; Prabhu RS; Owonikoko TK; Lawson DH; Switchenko J; Beitler JJ -
A randomised, phase II study of intetumumab, an anti-v-integrin mAb, alone and with dacarbazine in stage IV melanoma.
Br J Cancer Volume: 105 Page(s): 346 - 352
07/26/2011 Authors: O'Day S; Pavlick A; Loquai C; Lawson D; Gutzmer R; Richards J; Schadendorf D; Thompson JA; Gonzalez R; Trefzer U -
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
N Engl J Med Volume: 364 Page(s): 2119 - 2127
06/02/2011 Authors: Schwartzentruber DJ; Lawson DH; Richards JM; Conry RM; Miller DM; Treisman J; Gailani F; Riley L; Conlon K; Pockaj B -
Melanoma quality of life: pilot study using utility measurements.
Arch Dermatol Volume: 147 Page(s): 353 - 354
03/01/2011 Authors: King SMC; Bonaccorsi P; Bendeck S; Hadley J; Puttgen K; Kolm PG; Veledar E; Lawson D; Chen SC -
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.
Invest New Drugs Volume: 29 Page(s): 161 - 166
02/01/2011 Authors: Lewis KD; Samlowski W; Ward J; Catlett J; Cranmer L; Kirkwood J; Lawson D; Whitman E; Gonzalez R -
Mucosal Melanoma Of The Head and Neck: A Population-based Analysis, 1973-2007
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Volume: 81 Page(s): S533 - S533
01/01/2011 Authors: Marcus DM; Marcus RP; Prabhu RS; Owonikoko TK; Lawson DH; Beitler JJ -
Utility of lymph node assessment for atypical spitzoid melanocytic neoplasms.
Ann Surg Oncol Volume: 17 Page(s): 2471 - 2475
09/01/2010 Authors: Ghazi B; Carlson GW; Murray DR; Gow KW; Page A; Durham M; Kooby DA; Parker D; Rapkin L; Lawson DH -
Phase H trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Lutzky J; Lawson DH; Enriquez-Nunez Y; Gabrilovich D -
The role of radio-surgery in patients with metastatic melanoma to the brain
Volume: 28
05/20/2010 Authors: Lowe MC; Cavitt A; Shelton J; Crocker IR; Pan L; Lawson DH; Carlson GW; Delman KA; Rizzo M -
Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Kauh JS; Harvey RD; Lawson DH; Owonikoko TK; Tighiouart M; Ramalingam SS; Shin DM; Lewis CM; El-Rayes BF; Khuri FR -
E4697: Phase III cooperative group studt of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Lawson DH; Lee SJ; Tarhini AA; Margolin KA; Ernstoff MS; Kirkwood JM -
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
J Clin Oncol Volume: 27 Page(s): 5452 - 5458
11/10/2009 Authors: O'Day S; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Haddad J; Kong S; Williams A; Jacobson E -
Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy.
Clin Trials Volume: 6 Page(s): 480 - 490
10/01/2009 Authors: Auyeung SF; Long Q; Royster EB; Murthy S; McNutt MD; Lawson D; Miller A; Manatunga A; Musselman DL -
A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Volume: 27
06/20/2009 Authors: Schwartzentruber DJ; Lawson D; Richards J; Conry RM; Miller D; Triesman J; Gailani F; Riley LB; Vena D; Hwu P -
Randomized phase II study of the safety and efficacy of a human anti-alpha v integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results
Volume: 27
05/20/2009 Authors: Loquai C; Pavlick A; Lawson D; Gutzmer R; Richards J; Gore ME; de Boer CJ; Uhlar C; Lang Z; O'Day S -
Activation of Neuroendocrine Pathways by IL-2 Administration in Patients with Malignant Melanoma
Volume: 65 Page(s): 67S - 67S
04/15/2009 Authors: Royster EB; Graciaa DS; Trimble LM; Miller AH; Musselman DL -
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
J Immunother Volume: 32 Page(s): 322 - 324
04/01/2009 Authors: Akhtari M; Waller EK; Jaye DL; Lawson DH; Ibrahim R; Papadopoulos NE; Arellano ML -
Melanomas without an Epidermal Component: Metastatic or Unique Primary Lesions?
Volume: 16 Page(s): 95 - 96
02/01/2009 Authors: Singh KA; Carlson GW; Murray D; Hestley A; Rizzo M; Kooby D; Staley C; Lawson D; Delman K -
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Cancer Volume: 113 Page(s): 2139 - 2145
10/15/2008 Authors: Atkins MB; Sosman JA; Agarwala S; Logan T; Clark JI; Ernstoff MS; Lawson D; Dutcher JP; Weiss G; Curti B -
The quality of life impact of melanoma
Volume: 128 Page(s): 2554 - 2554
10/01/2008 Authors: King SC; Bonacocorsi P; Bendeck S; Hadley J; Kolm PG; Williams J; Lawson D; Chen SC -
ELESCLOMOL (FORMERLY STA-4783) AND PACLITAXEL IN STAGE IV METASTATIC MELANOMA (MM): 2-YEAR OVERALL SURVIVAL (OS)
Volume: 19 Page(s): 240 - 240
09/01/2008 Authors: O'Day SJ; Gonzalez R; Weber R; Hutchins LF; Anderson CM; Williams KN; Kong S; Jacobson E; Lawson D -
Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): Subgroup analysis by prior chemotherapy
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Gonzalez R; Lawson DH; Weber RW; Hutchins LF; Anderson CM; Williams KN; Kong S; Jacobson E; O'Day SJ -
Long term follow-up of sentinel lymph node biopsy in atypical spitzoid melanocytic neoplasms
Volume: 15 Page(s): 18 - 18
02/01/2008 Authors: Ghazi B; Carlson G; Durham M; Rapkin L; Murray D; Lawson D; Hestley A; Gow K; Kooby D; Staley C -
A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.
MOLECULAR CANCER THERAPEUTICS Volume: 6 Page(s): 3385S - 3385S
12/01/2007 Authors: Alexandrescu DT; Gonzales R; Lewis K; Samlowski W; Cranmer L; Catlett J; Kirkwood J; Whitman E; Lawson D; Bartels P -
Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.
Neuropsychopharmacology Volume: 32 Page(s): 2384 - 2392
11/01/2007 Authors: Capuron L; Pagnoni G; Demetrashvili MF; Lawson DH; Fornwalt FB; Woolwine B; Berns GS; Nemeroff CB; Miller AH -
Oxidative stress induction: an old idea whose time has come. MOA and clinical correlates of the oxidative stress inducer STA-478
Volume: 5 Page(s): 396 - 396
09/01/2007 Authors: Williams A; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Jacobson E; Bertin J; Kirshner J; O'Day S -
Routine staging of asymptomatic patients with ulcerated T3 and T4 primary melanomas does not detect distant metastases
Volume: 14 Page(s): 113 - 114
02/01/2007 Authors: Schwartz J; Murray DR; Lawson DH; Kooby DA; Staley CA; Rizzo M; Hestley A; Carlson GW; Delman KA -
YM155, a novel survivin suppressant, demonstrates activity in subjects with stage III or IV melanoma
Volume: 18 Page(s): 40 - 40
01/01/2007 Authors: Gonzalez R; Samlowski W; Cranmer L; Catlett J; Whitman E; Lawson D; Lewis K; Drake T; Bartels P; Buell D -
Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
Dermatol Surg Volume: 33 Page(s): 11 - 16
01/01/2007 Authors: Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC -
Despite a decreased incidence of positive sentinel lymph nodes, advanced age is associated with increased incidence of distant recurrences in patients with melanoma
Volume: 13 Page(s): 63 - 63
02/01/2006 Authors: Delman KA; Murray DR; Lawson DH; Tighiouart M; Solomon AR; Hestley A; Carlson GW -
A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
J Clin Psychiatry Volume: 67 Page(s): 288 - 296
02/01/2006 Authors: Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D -
Increased basal ganglia activity during interferon-alpha therapy for malignant melanoma: Relationship with neurovegetative symptoms
Volume: 30 Page(s): S222 - S223
12/01/2005 Authors: Capuron L; Pagnoni G; Demitrashvili M; Lawson DH; Berns GS; Nemeroff CB; Miller AH -
A phase 2 study of talabostat in patients with stage IV melanoma
Volume: 28 Page(s): 626 - 626
11/01/2005 Authors: Gajewski TF; Lawson DH; Redman BG; Cunningham C; Agarwala S; Ernstoff MS; Haltom EJ; Gregoire L; Uprichard MGJ -
A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, +/- dacarbazine (DTIC) in patients with metastatic melanoma (MM)
Volume: 28 Page(s): 643 - 644
11/01/2005 Authors: Hersey P; Sosman J; O'Day S; Richards J; Bedikian A; Gonzalez R; Sharfman W; Weber R; Logan T; Lawson D -
Choices in adjuvant therapy of melanoma.
Cancer Control Volume: 12 Page(s): 236 - 241
10/01/2005 Authors: Lawson DH -
A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma.
Volume: 23 Page(s): 723S - 723S
06/01/2005 Authors: Atkins MB; Sosman J; Agarwala S; Logan T; Clark J; Ernstoff M; Lawson D; Dutcher J; Weiss G; Urba W -
Activated caspase 3 expression in hepatocellular carcinoma
Volume: 85 Page(s): 288A - 288A
01/01/2005 Authors: Taylor K; Lawson D; Cotsonis G; Fields A; Cohen C -
alpha-Methylacyl coenzyme a racemase (P504S antibody) expression in hepatocellular carcinoma
Volume: 85 Page(s): 287A - 287A
01/01/2005 Authors: Taylor K; Lawson D; Cotsonis G; Fields A; Cohen C -
alpha-Methylacyl coenzyme A racemase (P504S antibody) expression in hepatocellular carcinoma
Volume: 18 Page(s): 287A - 287A
01/01/2005 Authors: Taylor K; Lawson D; Cotsonis G; Fields A; Cohen C -
Activated caspase 3 expression in hepatocellular carcinoma
Volume: 18 Page(s): 288A - 288A
01/01/2005 Authors: Taylor K; Lawson D; Cotsonis G; Fields A; Cohen C -
Epidermal growth factor receptor (EGFR) expression in colorectal carcinoma: Image cytometric quantitation
Volume: 18 Page(s): 329A - 330A
01/01/2005 Authors: Gupta M; Costonis G; Lawson D; Cohen C -
Claudin-7 expression in renal epithelial neoplasms: A candidate immunohistochemical marker for chromophobe renal cell carcinoma identified by gene expression profiling
Volume: 18 Page(s): 146A - 146A
01/01/2005 Authors: Hornsby CD; Yin-Goen Q; Cohen C; Lawson D; Young AN; Amin MB -
Correlation of the response of recurrent malignant gliomas treated with interferon alpha with tumor interferon alpha gene content.
Int J Oncol Volume: 25 Page(s): 419 - 427
08/01/2004 Authors: Olson JJ; James CD; Lawson D; Hunter S; Tang G; Billingsley J -
A phase I/II trial of BMS-247550 for patients with recurrent high-grade gliomas.
Volume: 22 Page(s): 118S - 118S
07/15/2004 Authors: Peereboom D; Carson K; Lawson D; Lesser G; Supko J; Grossman S -
Plasma homocysteine and immune activation in patients with malignant melanoma undergoing treatment with IFN-alpha.
J Interferon Cytokine Res Volume: 24 Page(s): 311 - 317
05/01/2004 Authors: Frick B; Capuron L; Schrcksnadel K; Musselman DL; Lawson DH; Nemeroff CB; Miller AH; Fuchs D -
Update on the systemic treatment of malignant melanoma.
Semin Oncol Volume: 31 Page(s): 33 - 37
04/01/2004 Authors: Lawson DH -
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.
Biol Psychiatry Volume: 54 Page(s): 906 - 914
11/01/2003 Authors: Capuron L; Neurauter G; Musselman DL; Lawson DH; Nemeroff CB; Fuchs D; Miller AH -
Rapid immunohistochemistry of sentinel lymph nodes for metastatic melanoma.
Hum Pathol Volume: 34 Page(s): 797 - 802
08/01/2003 Authors: Eudy GE; Carlson GW; Murray DR; Waldrop SM; Lawson D; Cohen C -
Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.
Am J Psychiatry Volume: 160 Page(s): 1342 - 1345
07/01/2003 Authors: Capuron L; Raison CL; Musselman DL; Lawson DH; Nemeroff CB; Miller AH -
Paroxetine versus placebo for the prevention of interferon-induced depression
PSYCHO-ONCOLOGY Volume: 12 Page(s): S146 - S146
06/01/2003 Authors: Demetrashvili M; Musselman D; Lawson D -
Rapid immunohistochemistry for cytokeratin in the intraoperative evaluation of sentinel lymph nodes for metastatic breast carcinoma.
Appl Immunohistochem Mol Morphol Volume: 11 Page(s): 45 - 50
03/01/2003 Authors: Beach RA; Lawson D; Waldrop SM; Cohen C -
Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Cytometry Volume: 50 Page(s): 203 - 209
08/15/2002 Authors: Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C -
Current management of depression in cancer patients - The Schwartz/Lander/Chochinov article reviewed
ONCOLOGY-NEW YORK Volume: 16 Page(s): 1110 - +
08/01/2002 Authors: Musselman DL; Lawson D; Miller AH -
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
Neuropsychopharmacology Volume: 26 Page(s): 643 - 652
05/01/2002 Authors: Capuron L; Gumnick JF; Musselman DL; Lawson DH; Reemsnyder A; Nemeroff CB; Miller AH -
Melanoma growth stimulatory activity in primary malignant melanoma: prognostic significance.
Mod Pathol Volume: 15 Page(s): 532 - 537
05/01/2002 Authors: Middleman BR; Friedman M; Lawson DH; DeRose PB; Cohen C -
Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization.
Mol Vis Volume: 8 Page(s): 119 - 126
04/21/2002 Authors: Grossniklaus HE; Ling JX; Wallace TM; Dithmar S; Lawson DH; Cohen C; Elner VM; Elner SG; Sternberg P -
Retinopathy associated with high-dose interferon alfa-2b therapy.
Am J Ophthalmol Volume: 131 Page(s): 782 - 787
06/01/2001 Authors: Hejny C; Sternberg P; Lawson DH; Greiner K; Aaberg TM -
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
N Engl J Med Volume: 344 Page(s): 961 - 966
03/29/2001 Authors: Musselman DL; Lawson DH; Gumnick JF; Manatunga AK; Penna S; Goodkin RS; Greiner K; Nemeroff CB; Miller AH -
Rapid immunohistochemistry (RIHC) for cytokeratin (CK) in the intraoperative evaluation of sentinel lymph nodes (SLNs) in breast cancer patients
LABORATORY INVESTIGATION Volume: 81 Page(s): 21A - 21A
01/01/2001 Authors: Beach RA; Lawson D; Waldrop SM; Cohen C -
Rapid immunohistochemistry (RIHC) for cytokeratin (CK) in the intraoperative evaluation of sentinel lymph nodes (SLNs) in breast cancer patients
MODERN PATHOLOGY Volume: 14 Page(s): 21A - 21A
01/01/2001 Authors: Beach RA; Lawson D; Waldrop SM; Cohen C -
Rapid immunohistochemistry (RIHC) of sentinel lymph nodes (SLN) for malignant melanoma (MM)
MODERN PATHOLOGY Volume: 14 Page(s): 232A - 232A
01/01/2001 Authors: Eudy GE; Carlson GW; Murray DR; Waldrop SM; Lawson D; Cohen C -
Rapid immunohistochemistry (RIHC) of sentinel lymph nodes (SLN) for malignant melanoma (MM)
LABORATORY INVESTIGATION Volume: 81 Page(s): 232A - 232A
01/01/2001 Authors: Eudy GE; Carlson GW; Murray DR; Waldrop SM; Lawson D; Cohen C -
Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study.
Arch Ophthalmol Volume: 118 Page(s): 1085 - 1089
08/01/2000 Authors: Dithmar S; Rusciano D; Lynn MJ; Lawson DH; Armstrong CA; Grossniklaus HE -
Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma?
J Clin Oncol Volume: 18 Page(s): 1603 - 1605
04/01/2000 Authors: Lawson D; Kirkwood JM -
Retinopathy associated with high dose interferon alfa therapy.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Volume: 41 Page(s): S357 - S357
03/15/2000 Authors: Hejny C; Sternberg P; Lawson D; Greiner K; Aaberg T -
Interferon alpha-2b treatment in a murine model for metastatic ocular melanoma.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Volume: 41 Page(s): S110 - S110
03/15/2000 Authors: Dithmar S; Rusciano D; Lawson DH; Grossniklaus HE -
Bcl-2: bax and bcl-2: Bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: correlation with prognosis.
Cytometry Volume: 42 Page(s): 61 - 66
02/15/2000 Authors: Lohmann CM; League AA; Clark WS; Lawson D; DeRose PB; Cohen C -
Paroxetine pretreatment reduces interferon-alpha-induced depression
BIOLOGICAL PSYCHIATRY Volume: 45 Page(s): 110S - 110S
04/15/1999 Authors: Musselman DL; Lawson DH; Penna S; Pearce BD; Su C; Nemeroff CB; Miller AH -
Quantitation of angiogenesis (factor VIII, CD31) visually and by image cytometry in renal cell carcinomas (RCCs): Prognostic significance
LABORATORY INVESTIGATION Volume: 79 Page(s): 156A - 156A
01/01/1999 Authors: Lohmann C; Fields A; Schiller A; Cotsonis G; Lawson D; Cohen C -
Hepatocellular carcinoma (HCC) and markers of apoptosis (bcl-2, bax, anti bcl-x): prognostic significance
LABORATORY INVESTIGATION Volume: 79 Page(s): 162A - 162A
01/01/1999 Authors: Garcia EJ; Lawson D; Cotsonis G; Cohen C -
Use of a novel marker-calponin (CALP) for myoepithelial cells (MEC) in fine needle aspirates (FNA) of papillary breast lesions
LABORATORY INVESTIGATION Volume: 79 Page(s): 49A - 49A
01/01/1999 Authors: Mosunjac MB; Lewis MM; Lawson DH; Cohen C -
Expression of apoptotic markers and their ratios in renal cell carcinoma: Prognostic significance
LABORATORY INVESTIGATION Volume: 79 Page(s): 155A - 155A
01/01/1999 Authors: Fields AC; Lohmann CM; Schiller AB; Cotsonis G; Lawson DH; DeRose PB; Cohen C -
Image cytometric bcl-2 : bax and bcl-2 : bcl-x ratios in invasive breast carcinoma - correlation with prognosis
LABORATORY INVESTIGATION Volume: 78 Page(s): 27A - 27A
01/01/1998 Authors: Schiller AB; Clark WS; Lawson D; DeRose PB; Cohen C -
Expression of tissue factor in infiltrating breast carcinoma - Prognostic significance
LABORATORY INVESTIGATION Volume: 78 Page(s): 30A - 30A
01/01/1998 Authors: Wallace TM; Schiller AB; Clark WS; Lawson D; Cohen C -
p53 protein and MIB-1 expression as prognostic markers in invasive breast carcinoma
MODERN PATHOLOGY Volume: 11 Page(s): 23A - 23A
01/01/1998 Authors: Middleman BR; Schiller AB; Clark WS; Lawson DH; Cohen C -
p53 protein and MIB-1 expression as prognostic markers in invasive breast carcinoma
LABORATORY INVESTIGATION Volume: 78 Page(s): 23A - 23A
01/01/1998 Authors: Middleman BR; Schiller AB; Clark WS; Lawson DH; Cohen C -
Image cytometric bcl-2 : bax and bcl-2 : bcl-x ratios in invasive breast carcinoma - Correlation with prognosis
MODERN PATHOLOGY Volume: 11 Page(s): 27A - 27A
01/01/1998 Authors: Schiller AB; Clark WS; Lawson D; DeRose PB; Cohen C -
Expression of tissue factor in infiltrating breast carcinoma prognostic significance
MODERN PATHOLOGY Volume: 11 Page(s): 30A - 30A
01/01/1998 Authors: Wallace TM; Schiller AB; Clark WS; Lawson D; Cohen C -
Prognostic significance of p53 and retinoblastoma (Rb) suppressor genes in prostatic adenocarcinoma.
LABORATORY INVESTIGATION Volume: 76 Page(s): 467 - 467
01/01/1997 Authors: Middleman BR; Goel A; Lawson D; DeRose PB; Cohen C -
Immediate breast reconstruction for stage III breast cancer using transverse rectus abdominis musculocutaneous (TRAM) flap.
Ann Surg Oncol Volume: 3 Page(s): 375 - 380
07/01/1996 Authors: Styblo TM; Lewis MM; Carlson GW; Murray DR; Wood WC; Lawson D; Landry J; Hughes L; Nahai F; Bostwick J -
MELANOMA GROWTH-STIMULATORY ACTIVITY IN PRIMARY MALIGNANT-MELANOMA - PROGNOSTIC-SIGNIFICANCE
LABORATORY INVESTIGATION Volume: 72 Page(s): A49 - A49
01/01/1995 Authors: MIDDLEMAN BR; FRIEDMAN M; LAWSON D; DEROSE PB; COHEN C -
Conservative treatment of early-stage breast cancer. The Emory experience.
Am J Clin Oncol Volume: 17 Page(s): 348 - 352
08/01/1994 Authors: Smith RG; Landry JC; Wood WC; Styblo T; Hughes LL; Lynn M; York RM; Powell RW; Butker E; Lawson DH -
Cancer-related urinary proteinase inhibitor, EDC1: a new method for its isolation and evidence for multiple forms.
J Cell Biochem Volume: 50 Page(s): 227 - 236
11/01/1992 Authors: Chawla RK; Lawson DH; Ahmad M; Travis J -
The review of medicines in the United Kingdom.
Br J Clin Pharmacol Volume: 33 Page(s): 583 - 587
06/01/1992 Authors: Winship K; Hepburn D; Lawson DH -
Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
Arch Surg Volume: 126 Page(s): 898 - 903
07/01/1991 Authors: Koretz MJ; Lawson DH; York RM; Graham SD; Murray DR; Gillespie TM; Levitt D; Sell KM -
ROLE OF TRANSFERRIN IN GROWTH OF MELANOMA-CELLS
CLINICAL RESEARCH Volume: 39 Page(s): A451 - A451
04/01/1991 Authors: LAWSON DH; BORDONI RE; CHAWLA RK -
Plasma inter-alpha-trypsin inhibitor-related urinary glycoprotein EDC1 inhibits the growth of a Burkitt's lymphoma cell line.
J Cell Biochem Volume: 42 Page(s): 207 - 217
04/01/1990 Authors: Chawla RK; Lawson DH; Travis J -
Preparation of a monoclonal antibody to a melanoma growth-stimulatory activity released into serum-free culture medium by Hs0294 malignant melanoma cells.
J Cell Biochem Volume: 34 Page(s): 169 - 185
07/01/1987 Authors: Lawson DH; Thomas HG; Roy RG; Gordon DS; Chawla RK; Nixon DW; Richmond A -
COVALENT STRUCTURE OF CANCER-RELATED URINARY PROTEINASE-INHIBITOR EDCL
FEDERATION PROCEEDINGS Volume: 46 Page(s): 2224 - 2224
05/01/1987 Authors: CHAWLA RK; LAWSON DH -
Serum alpha-1 proteinase inhibitor in advanced cancer: mass variants and functionally inert forms.
Cancer Res Volume: 47 Page(s): 1179 - 1184
02/15/1987 Authors: Chawla RK; Lawson DH; Sarma PR; Nixon DW; Travis J -
GROWTH-PROMOTING ACTIVITY FOR HUMAN-MELANOMA CELLS IN URINE FROM A PATIENT WITH MELANOMA
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 27 Page(s): 216 - 216
03/01/1986 Authors: LAWSON DH; CHAWLA RK -
Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas.
J Invest Dermatol Volume: 86 Page(s): 295 - 302
03/01/1986 Authors: Richmond A; Fine R; Murray D; Lawson DH; Priest JH -
Characterization of autostimulatory and transforming growth factors from human melanoma cells.
Cancer Res Volume: 45 Page(s): 6390 - 6394
12/01/1985 Authors: Richmond A; Lawson DH; Nixon DW; Chawla RK -
The effect of a phenylalanine and tyrosine restricted diet on elemental balance studies and plasma aminograms of patients with disseminated malignant melanoma.
Am J Clin Nutr Volume: 41 Page(s): 73 - 84
01/01/1985 Authors: Lawson DH; Stockton LH; Bleier JC; Acosta PB; Heymsfield SB; Nixon DW -
GROWTH-FACTOR AND CYTOGENETIC ABNORMALITIES IN MALIGNANT MELANOMAS AND NON-MALIGNANT NEVI
JOURNAL OF INVESTIGATIVE DERMATOLOGY Volume: 84 Page(s): 320 - 320
01/01/1985 Authors: RICHMOND A; FERNANDEZ J; ROY RG; ENGEL C; FINE R; MURRAY D; LAWSON DH; PRIEST J -
GROWTH-FACTOR AND CYTOGENETIC ABNORMALITIES IN MALIGNANT MELANOMAS AND NON-MALIGNANT NEVI
CLINICAL RESEARCH Volume: 33 Page(s): A678 - A678
01/01/1985 Authors: RICHMOND A; FERNANDEZ J; ROY RG; ENGEL C; FINE R; MURRAY D; LAWSON DH; PRIEST J -
BIOCHEMICAL-CHARACTERIZATION OF SERUM ALPHA-1-PROTEINASE INHIBITOR IN CANCER
FEDERATION PROCEEDINGS Volume: 44 Page(s): 1431 - 1431
01/01/1985 Authors: CHAWLA R; LAWSON D; FULLER M -
Abnormal profile of serum proteinase inhibitors in cancer patients.
Cancer Res Volume: 44 Page(s): 2718 - 2723
06/01/1984 Authors: Chawla RK; Rausch DJ; Miller FW; Vogler WR; Lawson DH -
MITOGENIC AND TRANSFORMING GROWTH-FACTORS (TGFS) PRODUCED BY HUMAN-MELANOMA CELLS
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 25 Page(s): 214 - 214
01/01/1984 Authors: RICHMOND A; LAWSON DH; NIXON DW; CHAWLA RK -
Urinary cancer-related protein EDC1 and serum inter-alpha trypsin inhibitor in breast cancer.
Tumour Biol Volume: 5 Page(s): 351 - 363
01/01/1984 Authors: Chawla RK; Miller FW; Lawson DH; Nixon DW -
CHARACTERIZATION OF AN AUTOSTIMULATORY MONOLAYER MITOGEN FROM HUMAN-MELANOMA CELLS
JOURNAL OF CELL BIOLOGY Volume: 99 Page(s): A272 - A272
01/01/1984 Authors: RICHMOND A; LAWSON DH; CHAWLA RK; ROY RG -
Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin.
Cancer Volume: 52 Page(s): 2220 - 2222
12/15/1983 Authors: York RM; Lawson DH; McKay J -
Nutritional support of the cancer patient.
Hosp Formul Volume: 18 Page(s): 616 - 619
06/01/1983 Authors: Nixon DW; Lawson DH -
Extraction of a melanoma growth-stimulatory activity from culture medium conditioned by the Hs0294 human melanoma cell line.
Cancer Res Volume: 43 Page(s): 2106 - 2112
05/01/1983 Authors: Richmond A; Lawson DH; Nixon DW; Stevens JS; Chawla RK -
Evaluation of transsphenoidal hypophysectomy in the management of patients with advanced malignant melanoma.
Cancer Volume: 51 Page(s): 1541 - 1545
04/15/1983 Authors: Lawson DH; Nixon DW; Black ML; Tindall GT; Barnes DA; Faraj BA; Ali FM; Camp VM; Richmond A -
In vitro growth promotion in human malignant melanoma cells by fibroblast growth factor.
Cancer Res Volume: 42 Page(s): 3175 - 3180
08/01/1982 Authors: Richmond A; Lawson DH; Nixon DW; Stevens JS; Chawla RK -
Metabolic approaches to cancer cachexia.
Annu Rev Nutr Volume: 2 Page(s): 277 - 301
01/01/1982 Authors: Lawson DH; Richmond A; Nixon DW; Rudman D -
HORMONAL RESPONSIVENESS OF THE HUMAN-MALIGNANT MELANOMA CELL-LINE HS0294
FEDERATION PROCEEDINGS Volume: 41 Page(s): 736 - 736
01/01/1982 Authors: LAWSON DH; RICHMOND A; CHAWLA RK; NIXON DW -
COPURIFICATION OF AN AUTOSTIMULATORY AND TRANSFORMING GROWTH-ACTIVITY FROM HUMAN-MELANOMA CELLS
FEDERATION PROCEEDINGS Volume: 41 Page(s): 855 - 855
01/01/1982 Authors: RICHMOND A; LAWSON DH; CHAWLA RK; NIXON DW -
Energy malabsorption: measurement and nutritional consequences.
Am J Clin Nutr Volume: 34 Page(s): 1954 - 1960
09/01/1981 Authors: Heymsfield SB; Smith J; Kasriel S; Barlow J; Lynn MJ; Nixon D; Lawson DH -
Hyperalimentation of the cancer patient with protein-calorie undernutrition.
Cancer Res Volume: 41 Page(s): 2038 - 2045
06/01/1981 Authors: Nixon DW; Lawson DH; Kutner M; Ansley J; Schwarz M; Heymsfield S; Chawla R; Cartwright TH; Rudman D -
Dermatologic changes after systemic cancer therapy.
Cutis Volume: 27 Page(s): 181 - 194
02/01/1981 Authors: Nixon DW; Pirozzi D; York RM; Black M; Lawson DH -
Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine.
Clin Chem Volume: 27 Page(s): 108 - 112
01/01/1981 Authors: Faraj BA; Lawson DH; Nixon DW; Murray DR; Camp VM; Ali FM; Black M; Stacciarini W; Tarcan Y -
AUTOSTIMULATION OF GROWTH BY A TUMOR DERIVED GROWTH-FACTOR FROM THE HUMAN-MALIGNANT MELANOMA CELL-LINE HS0294
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 22 Page(s): 54 - 54
01/01/1981 Authors: RICHMOND A; LAWSON DH; NIXON DW; CHAWLA RK; STEVENS JS; RUDMAN D -
PLASMA INTER-ALPHA TRYPSIN-INHIBITOR (IATI) IN METASTATIC BREAST-CANCER
ONCODEVELOPMENTAL BIOLOGY AND MEDICINE Volume: 2 Page(s): P20 - P20
01/01/1981 Authors: CHAWLA RK; MILLER FW; LAWSON DH; RICHMOND A; NIXON DW; RUDMAN D -
Enteral versus parenteral nutritional support in cancer patients.
Cancer Treat Rep Volume: 65 Suppl 5 Page(s): 101 - 106
01/01/1981 Authors: Lawson DH; Nixon DW; Kutner MH; Heymsfield SB; Rudman D; Moffitt S; Ansley J; Chawla R -
INVITRO GROWTH PROMOTION IN HUMAN-MALIGNANT MELANOMA-CELLS BY FIBROBLAST GROWTH-FACTOR (FGF)
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 22 Page(s): 56 - 56
01/01/1981 Authors: LAWSON DH; RICHMOND A; CHAWLA RK; STEVENS JS; RUDMAN D -
EVIDENCE FOR ARGININE AT THE REACTIVE SITE OF THE CANCER-RELATED URINARY TRYPSIN-INHIBITOR EDC1
FEDERATION PROCEEDINGS Volume: 40 Page(s): 1602 - 1602
01/01/1981 Authors: CHAWLA RK; MILLER FW; RICHMOND JA; LAWSON DH; RUDMAN D -
Total parenteral nutrition as an adjunct to chemotherapy of metastatic colorectal cancer.
Cancer Treat Rep Volume: 65 Suppl 5 Page(s): 121 - 128
01/01/1981 Authors: Nixon DW; Moffitt S; Lawson DH; Ansley J; Lynn MJ; Kutner MH; Heymsfield SB; Wesley M; Chawla R; Rudman D -
CANCER RELATED URINARY GLYCOPROTEIN EDC1 IN ADENOCARCINOMA OF BREAST
FEDERATION PROCEEDINGS Volume: 40 Page(s): 832 - 832
01/01/1981 Authors: CHAWLA RK; MILLER FW; LAWSON DH; RICHMOND A; NIXON DW -
Effect of plasma inter-alpha trypsin inhibitor and cancer-related glycoprotein EDC1 on phytohemagglutinin-induced thymidine uptake in lymphocytes.
Cancer Res Volume: 40 Page(s): 4187 - 4191
11/01/1980 Authors: Chawla RK; Lawson DH; Richmond A; Rudman D -
Elevated plasma and urinary guanosine 3':5'-monophosphate and increased production rate in patients with neoplastic diseases.
Cancer Res Volume: 40 Page(s): 3915 - 3920
11/01/1980 Authors: Chawla RK; Shlaer SM; Lawson DH; Murray TG; Schmidt F; Shoji M; Nixon DW; Richmond A; Rudman D -
Protein-calorie undernutrition in hospitalized cancer patients.
Am J Med Volume: 68 Page(s): 683 - 690
05/01/1980 Authors: Nixon DW; Heymsfield SB; Cohen AE; Kutner MH; Ansley J; Lawson DH; Rudman D -
CENTRAL INTRAVENOUS HYPERALIMENTATION VS AD-LIBITUM FEEDING IN COLON CANCER-PATIENTS ON CHEMOTHERAPY
CLINICAL RESEARCH Volume: 28 Page(s): A599 - A599
01/01/1980 Authors: NIXON DW; MOFFITT S; LAWSON DH; ANSLEY J; LYNN M; KUTNER M; HEYMSFIELD S; RUDMAN D -
ENERGY MALABSORPTION
CLINICAL RESEARCH Volume: 28 Page(s): A230 - A230
01/01/1980 Authors: HEYMSFIELD S; LAWSON D; TILL J; KASRIEL S; BLACK J -
INVITRO SUPPRESSION OF LYMPHOCYTE-RESPONSE TO PHA BY URINARY CANCER-RELATED GLYCOPROTEIN EDCL
CLINICAL RESEARCH Volume: 28 Page(s): A525 - A525
01/01/1980 Authors: CHAWLA RK; RICHMOND A; LAWSON DH; RUDMAN D -
GUANOSINE 3'-5' MONOPHOSPHATE IN CANCER
FEDERATION PROCEEDINGS Volume: 39 Page(s): 743 - 743
01/01/1980 Authors: CHAWLA RK; MURRAY TJ; LAWSON DH; SHOJI M; RUDMAN D -
PHARMACOKINETICS AND TOXICITY OF HIGH-DOSE METHOTREXATE WITH LEUCOVORIN RESCUE (HDMTX) FOLLOWED BY CIS-PLATINUM (DDP)
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 21 Page(s): 333 - 333
01/01/1980 Authors: LAWSON DH; YORK RM; VOGLER WR; ISRAILI ZH -
ENERGY MALABSORPTION - NUTRITIONAL CONSEQUENCES AND MEASUREMENT
CLINICAL RESEARCH Volume: 28 Page(s): A820 - A820
01/01/1980 Authors: HEYMSFIELD S; SMITH J; LAWSON D -
An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. A pilot study of the Southeastern Cancer Study Group.
Cancer Clin Trials Volume: 3 Page(s): 293 - 296
01/01/1980 Authors: Lawson D; Moore M; Smalley R -
CENTRAL INTRAVENOUS HYPERALIMENTATION VS ADLIBITUM FEEDING IN COLON CANCER-PATIENTS ON CHEMOTHERAPY
AMERICAN JOURNAL OF CLINICAL NUTRITION Volume: 33 Page(s): 917 - 917
01/01/1980 Authors: NIXON DW; MOFFITT S; LAWSON DH; ANSLEY J; LYNN M; KUTNER M; HEYMSFIELD S; RUDMAN D -
RADIOIMMUNOASSAY (RIA) OF 3-0-METHYLDOPAMINE (MDA) IN THE EVALUATION OF RESPONSE TO HYPOPHYSECTOMY (HYPOX) IN MALIGNANT-MELANOMA
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 21 Page(s): 173 - 173
01/01/1980 Authors: LAWSON D; FARAJ B; BLACK M; TINDALL G; RUDMAN D; BARNES D; CAMP V; ALI F -
Modern chemotherapy in the management of testicular tumors.
South Med J Volume: 72 Page(s): 1393 - 1398
11/01/1979 Authors: Lawson DH; Nixon DW -
ELEVATED PLASMA AND URINARY CYCLIC-GMP AND INCREASED PRODUCTION-RATE IN PATIENTS WITH NEOPLASTIC DISEASE
CLINICAL RESEARCH Volume: 27 Page(s): A759 - A759
01/01/1979 Authors: MURRAY T; LAWSON D; CHAWLA RK; RUDMAN D -
TRANS-SPHENOIDAL HYPOPHYSECTOMY FOR MALIGNANT-MELANOMA
CLINICAL RESEARCH Volume: 27 Page(s): A759 - A759
01/01/1979 Authors: LAWSON D; FARAJ B; BLACK M; NIXON D; RUDMAN D; BARNES D; CAMP V; ALI F; TINDALL G -
METHODS OF COLLECTION AND RESULTS OF TRANSFUSION OF GRANULOCYTES
EXPERIMENTAL HEMATOLOGY Volume: 6 Page(s): 93 - 93
01/01/1978 Authors: VOGLER WR; WINTON EF; LAWSON DH